• 1. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 4. Alt-proteins: A promising future
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Study of 1-Benzylindazole-3-carboxylic Acid (CAS 41354-03-4) and Its Applications in Chemical Biology and Medicine

The compound 1-benzylindazole-3-carboxylic acid (CAS 41354-03-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging roles in drug development. Recent studies highlight its structural uniqueness, which allows for interactions with various biological targets, making it a promising candidate for further investigation.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the synthesis and optimization of 1-benzylindazole-3-carboxylic acid derivatives to enhance their bioactivity. The study employed computational modeling and high-throughput screening to identify key structural modifications that improve binding affinity to target enzymes involved in inflammatory pathways. The results demonstrated that specific substitutions on the benzyl and indazole rings significantly increased inhibitory activity against cyclooxygenase-2 (COX-2), suggesting potential applications in anti-inflammatory therapies.

Another groundbreaking study, featured in Bioorganic & Medicinal Chemistry Letters, investigated the compound's role as a modulator of G-protein-coupled receptors (GPCRs). The research team synthesized a series of analogs and evaluated their efficacy in vitro. Their findings revealed that 1-benzylindazole-3-carboxylic acid exhibits selective agonism toward certain GPCR subtypes, which could pave the way for novel treatments for neurological disorders such as Parkinson's disease and schizophrenia. The study also emphasized the compound's favorable pharmacokinetic profile, including good oral bioavailability and metabolic stability.

Recent advancements in analytical techniques have further elucidated the compound's mechanism of action. A 2024 paper in Analytical Chemistry detailed the use of mass spectrometry and NMR spectroscopy to characterize the metabolic pathways of 1-benzylindazole-3-carboxylic acid in human liver microsomes. The study identified major metabolites and proposed a comprehensive metabolic map, which is critical for assessing the compound's safety and efficacy in preclinical development. These insights are invaluable for optimizing dosage regimens and minimizing potential side effects in future clinical trials.

In addition to its therapeutic potential, 1-benzylindazole-3-carboxylic acid has also been explored as a tool compound in chemical biology. A recent publication in Nature Chemical Biology highlighted its use as a fluorescent probe for imaging intracellular enzyme activity. The compound's inherent fluorescence properties, combined with its ability to bind specific enzymes, enable real-time monitoring of enzymatic processes in live cells. This application opens new avenues for studying disease mechanisms and screening for enzyme inhibitors in high-content assays.

Despite these promising developments, challenges remain in the clinical translation of 1-benzylindazole-3-carboxylic acid-based therapies. Issues such as scalability of synthesis, off-target effects, and long-term toxicity need to be addressed in ongoing research. Collaborative efforts between academia and industry are essential to overcome these hurdles and accelerate the compound's transition from bench to bedside. Future studies should focus on structure-activity relationship (SAR) optimization and in vivo validation to fully realize its therapeutic potential.

In conclusion, 1-benzylindazole-3-carboxylic acid (CAS 41354-03-4) represents a multifaceted compound with significant implications for chemical biology and medicine. Its diverse pharmacological activities, coupled with recent technological advancements, position it as a valuable asset in drug discovery and development. Continued research and innovation will undoubtedly uncover new applications and refine its utility in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)